CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation

[1]  M. Heneka,et al.  NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice , 2012, Nature.

[2]  D. Golenbock,et al.  Activation of the NLRP 3 Inflammasome , 2012 .

[3]  Moshe Levi,et al.  Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging , 2011, Journal of Lipid Research.

[4]  K. Moore,et al.  A High Content Drug Screen Identifies Ursolic Acid as an Inhibitor of Amyloid β Protein Interactions with Its Receptor CD36* , 2011, The Journal of Biological Chemistry.

[5]  Anna K Rieger,et al.  Cutting Edge: Reactive Oxygen Species Inhibitors Block Priming, but Not Activation, of the NLRP3 Inflammasome , 2011, The Journal of Immunology.

[6]  Xiangmei Zhou,et al.  A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.

[7]  T. Mitchell,et al.  Mechanism of Impaired NLRP3 Inflammasome Priming by Monophosphoryl Lipid A , 2011, Science Signaling.

[8]  D. Harats,et al.  Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α. , 2011, Biochemical and biophysical research communications.

[9]  R. Silverstein,et al.  A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling , 2010, Cardiovascular research.

[10]  A. Aderem,et al.  Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria , 2010, Nature Immunology.

[11]  Christine E. Becker,et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes , 2010, Nature Immunology.

[12]  Egil Lien,et al.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.

[13]  P. Kovanen,et al.  Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation , 2010, PloS one.

[14]  G. Guarda,et al.  Regulation of inflammasome activity , 2010, Immunology.

[15]  G. Abela.  Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. , 2010, Journal of clinical lipidology.

[16]  K. Reymann,et al.  Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity , 2010, Proceedings of the National Academy of Sciences.

[17]  K. Moore,et al.  CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer , 2009, Nature Immunology.

[18]  F. Maxfield,et al.  Chemical screen to reduce sterol accumulation in Niemann-Pick C disease cells identifies novel lysosomal acid lipase inhibitors. , 2009, Biochimica et biophysica acta.

[19]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[20]  G. Schmitz,et al.  Endolysosomal phospholipidosis and cytosolic lipid droplet storage and release in macrophages. , 2009, Biochimica et biophysica acta.

[21]  R. Silverstein,et al.  CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior , 2009, Science Signaling.

[22]  Olle Korsgren,et al.  Widespread amyloid deposition in transplanted human pancreatic islets. , 2008, The New England journal of medicine.

[23]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[24]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[25]  M. Febbraio,et al.  Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. , 2008, Cardiovascular research.

[26]  S. Werner,et al.  Active Caspase-1 Is a Regulator of Unconventional Protein Secretion , 2008, Cell.

[27]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[28]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[29]  V. Dixit,et al.  Cryopyrin activates the inflammasome in response to toxins and ATP , 2006, Nature.

[30]  K. Moore,et al.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. , 2005, The Journal of clinical investigation.

[31]  K. Moore,et al.  Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain , 2005, The Journal of cell biology.

[32]  B. Teusink,et al.  CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice Published, JLR Papers in Press, August 16, 2003. DOI 10.1194/jlr.M300143-JLR200 , 2003, Journal of Lipid Research.

[33]  K. Moore,et al.  CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.

[34]  J. Witztum,et al.  Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL , 2003, Nature Medicine.

[35]  K. Moore,et al.  Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages* , 2002, The Journal of Biological Chemistry.

[36]  K. Moore,et al.  A CD36-initiated Signaling Cascade Mediates Inflammatory Effects of β-Amyloid* , 2002, The Journal of Biological Chemistry.

[37]  A. Bonen,et al.  Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. , 2002, The Journal of clinical investigation.

[38]  K. Moore,et al.  A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. , 2002, The Journal of biological chemistry.

[39]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[40]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[41]  J. Morris,et al.  Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation , 1998, Cell and Tissue Research.

[42]  E. D. de Koning,et al.  Macrophages and pancreatic islet amyloidosis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[43]  C. Masters,et al.  Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides , 1997, Nature Medicine.

[44]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[45]  M. Su,et al.  Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. , 1995, Science.

[46]  R. Jackson,et al.  Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. , 1994, Journal of lipid research.

[47]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[48]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[49]  D. Selkoe,et al.  Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.

[50]  D. Teplow,et al.  Amyloid beta-peptide is produced by cultured cells during normal metabolism. , 1992, Nature.

[51]  C. Moyer,et al.  Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. , 1991, The American journal of pathology.

[52]  L. Rasmussen,et al.  The Modulatory Effect of Lipoproteins on the Release of Interleukin 1 by Human Peritoneal Macrophages Stimulated with β‐1,3‐d‐Polyglucose Derivatives , 1989, Scandinavian journal of immunology.

[53]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Selkoe,et al.  Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Turner,et al.  ISLET AMYLOID FORMED FROM DIABETES-ASSOCIATED PEPTIDE MAY BE PATHOGENIC IN TYPE-2 DIABETES , 1987, The Lancet.

[56]  D. W. Hayden,et al.  Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  C. Wiltschke,et al.  Differentiation of Rat Bone Marrow Cells Into Macrophages Under the Influence of Mouse L929 Cell Supernatant , 1987, Journal of leukocyte biology.